Skip to content
PubMed This is a summary of 69 peer-reviewed journal articles Updated
Hematology · Myeloid/Lymphoid Neoplasm with JAK2 Rearrangement

Myeloid/Lymphoid Neoplasm with JAK2 Rearrangement: A Patient Guide

At a Glance

A myeloid/lymphoid neoplasm with JAK2 rearrangement is a rare blood cancer caused by an acquired JAK2 gene fusion. Diagnosis identifies the fusion partner, while treatment may include off-label JAK inhibitors and, for eligible patients, donor stem cell transplant.

A diagnosis of a myeloid/lymphoid neoplasm (MLN) with a JAK2 rearrangement identifies a rare and complex form of blood cancer driven by an acquired genetic change. This condition belongs to a group of diseases defined by tyrosine kinase gene fusions, where a piece of the JAK2 gene breaks and fuses with another partner gene [1]. This fusion creates a protein that is permanently “switched on,” altering growth signaling and instructing your bone marrow to produce an overabundance of certain blood cells. The disease is uniquely versatile; it can manifest as a slow-moving, chronic condition (like a myeloproliferative neoplasm or MPN), present with low blood counts and marrow scarring, or transform into an aggressive, acute leukemia [2].

A hallmark of this diagnosis is often an elevated level of eosinophils, a type of white blood cell that can become highly inflammatory when overproduced. If left unmanaged and persistent, these cells can sometimes infiltrate and damage vital organs. The heart is particularly vulnerable to scarring and the formation of internal blood clots [3]. Because of this risk, your care team may assess your organ function closely and involve a cardio-oncologist if indicated by your symptoms or eosinophil levels. Successfully managing the disease requires a precise diagnosis that identifies your exact genetic fusion partner. This helps your doctors confirm the classification and provides clues about how the cancer may behave, though it cannot predict your individual future with certainty [4].

Because this is a very rare entity with limited clinical-trial evidence, there is no single universally established standard treatment. Modern treatment strategies often utilize targeted medications called JAK inhibitors (such as ruxolitinib) off-label for selected patients. These can effectively shrink an enlarged spleen and reduce debilitating symptoms like night sweats and fatigue, though responses can vary widely [5]. While these medications are a vital tool for stabilizing the disease, they are typically viewed as a bridge or a disease-control measure rather than a guaranteed cure. For eligible patients, an allogeneic stem cell transplant—replacing the faulty blood-making system with healthy donor cells—is an important, potentially curative option that may be considered early, though it carries substantial risks and is not guaranteed to cure the disease [4].

Because this condition is exceptionally rare, it is highly recommended to have your pathology reviewed and your initial treatment plan guided by a multidisciplinary team at an experienced academic or transplant center. Ongoing care can often be co-managed with your local hematologist. Navigating this diagnosis can feel overwhelming, but by working with a specialized team that understands the unique biology of the JAK2 fusion, you can move forward with an individualized plan designed to control the disease and protect your long-term health [1][4].

Common questions in this guide

What is a myeloid/lymphoid neoplasm with a JAK2 rearrangement?
It is a rare blood cancer caused by an acquired change that joins the JAK2 gene to another gene. This creates an always-active growth signal in blood-forming cells, and the disease can range from a chronic condition to an aggressive acute leukemia.
Why do eosinophil levels and heart health matter with this condition?
JAK2-rearranged disease can cause persistent overproduction of eosinophils, which are white blood cells that may inflame and damage organs. The heart can be especially vulnerable to scarring and blood clots, so your team may monitor heart function or involve a cardio-oncologist.
How is a JAK2-rearranged neoplasm diagnosed?
Diagnosis usually requires expert review of blood and bone marrow findings along with molecular testing to identify the exact gene fused with JAK2. Reviewing the pathology and fusion result helps confirm the disease classification and guide treatment planning.
What treatments may be used for a JAK2-rearranged neoplasm?
Because this condition is very rare, there is no single treatment plan for everyone. Selected patients may receive a JAK inhibitor such as ruxolitinib off-label to control disease, reduce spleen enlargement, and ease symptoms; an allogeneic stem cell transplant may be considered for eligible patients.
When should stem cell transplant be discussed?
An allogeneic stem cell transplant may be considered early for patients whose health and disease features make the procedure appropriate. It replaces the diseased blood-making system with cells from a donor and may offer a chance of long-term disease control, but it carries substantial risks and is not guaranteed to cure the disease.
Where should I seek care for this rare diagnosis?
Ask for pathology review and treatment planning from a multidisciplinary team at an experienced academic or transplant center. Your local hematologist may be able to coordinate ongoing care with that specialist team.

Get notified when new evidence is published on Myeloid/lymphoid neoplasm associated with JAK2 rearrangement.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (5)
  1. 1

    How I diagnose and treat myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.

    Reiter A, Metzgeroth G, Cross NCP

    Blood 2025; (145(16)):1758-1768 doi:10.1182/blood.2023022417.

    PMID: 39046810
  2. 2

    Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

    Tang G, Sydney Sir Philip JK, Weinberg O, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2019; (32(4)):490-498 doi:10.1038/s41379-018-0165-9.

    PMID: 30401948
  3. 3

    Hypereosinophilic syndrome: cardiac diagnosis and management.

    Mankad R, Bonnichsen C, Mankad S

    Heart (British Cardiac Society) 2016; (102(2)):100-6 doi:10.1136/heartjnl-2015-307959.

    PMID: 26567231
  4. 4

    Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

    Polverelli N, Hernández-Boluda JC, Onida F, et al.

    Blood 2025; (145(22)):2561-2573 doi:10.1182/blood.2024028000.

    PMID: 40106773
  5. 5

    PCM1-JAK2 Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature.

    Kaplan HG, Jin R, Bifulco CB, et al.

    The oncologist 2022; (27(8)):e661-e670 doi:10.1093/oncolo/oyac072.

    PMID: 35472244

This page is for informational purposes only and does not constitute medical advice. A hematologist and specialist team should interpret your JAK2 results and discuss treatment options for your situation.